Could a Mitochondria-Targeting pill help failing hearts?
NCT ID NCT05410873
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether MitoQ, a drug that targets cell energy centers, can improve heart function in 53 people with dilated cardiomyopathy. Participants took MitoQ or a placebo for several months while researchers measured heart energy levels and pumping ability using MRI scans. The goal was to see if reducing cell stress could help the heart work better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MitoQ (mitoquinol mesylate)
- What this could lead to
- If it works, this could point toward a new treatment that helps the heart work better in people with dilated cardiomyopathy.
- What could go wrong
- This is a small, early-phase trial with only 53 participants, so results may not apply to everyone. The drug may not improve heart function or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DILATED CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Brompton Hospital
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart scans may soon replace Needle-Based catheter tests
- Heart conditions in kids: study reveals impact on daily life and play
- Tiny study could unlock secrets of genetic heart failure
- Gene hunt launched for kids with heart muscle disease
- MRI scans could help decide who needs a heart defibrillator
- AI-Powered patch could replace ultrasound for heart checkups